Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.

[1]  J. S. Schneider,et al.  Astrocytic Responses to the Dopaminergic Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Cat and Mouse Brain , 1988, Journal of neuropathology and experimental neurology.

[2]  J. Langston,et al.  An electron microscopic study of MPTP-induced inclusion bodies in an old monkey , 1988, Brain Research.

[3]  R. M. Rose,et al.  Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem , 1988, Neuroscience.

[4]  D. German,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? , 1988, Neuroscience.

[5]  J. McKenzie,et al.  Regional and temporal effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine uptake sites in mouse brain , 1987, Journal of the Neurological Sciences.

[6]  R. Kalaria,et al.  Blood‐Brain Barrier Monoamine Oxidase: Enzyme Characterization in Cerebral Microvessels and Other Tissues from Six Mammalian Species, Including Human , 1987, Journal of neurochemistry.

[7]  P. Sonsalla,et al.  Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. , 1987, The Journal of pharmacology and experimental therapeutics.

[8]  R. Ramsay,et al.  Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[9]  C. Markham,et al.  Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP , 1987, Brain Research.

[10]  L. Olson,et al.  Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice , 1987, Brain Research.

[11]  R. Heikkila,et al.  Evaluation of the Biological Activity of Several Analogs of the Dopaminergic Neurotoxin 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[12]  W. Nicklas,et al.  IV. MPTP, MPP+ and mitochondrial function , 1987 .

[13]  J. Langston,et al.  Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra , 1987, Brain Research.

[14]  J. Langston,et al.  Older dopaminergic neurons do not recover from the effects of MPTP , 1987, Neuropharmacology.

[15]  D. Felten,et al.  Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults , 1986, Neuroscience Letters.

[16]  P. Sonsalla,et al.  The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. , 1986, European journal of pharmacology.

[17]  J W Langston,et al.  Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys , 1986, Annals of neurology.

[18]  D. Jacobowitz,et al.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.

[19]  F. Urbach,et al.  Mechanism of induction of Parkinson's disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Chemical and electrochemical characterization of a geminal-dimethyl-blocked analog of a postulated toxic metabolite. , 1986, Journal of the American Chemical Society.

[20]  R. Duvoisin,et al.  1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice. , 1986, European journal of pharmacology.

[21]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[22]  C. Markham,et al.  Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry , 1986, Experimental Neurology.

[23]  S. Snyder,et al.  MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. , 1986, Neurology.

[24]  R. Heikkila,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity. , 1986, European journal of pharmacology.

[25]  R. Ramsay,et al.  Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. , 1986, Biochemical and biophysical research communications.

[26]  R. Fuller,et al.  Mechanisms of MPTP (1-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice , 1985, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[27]  D. Cavalla,et al.  N‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Increases Acetylcholine and Decreases Dopamine in Mouse Striatum: Both Responses Are Blocked by Anticholinergic Drugs , 1985, Journal of neurochemistry.

[28]  R. Heikkila.  Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. , 1985, European journal of pharmacology.

[29]  I. Mitchell,et al.  Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.

[30]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[31]  E. Melamed,et al.  Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice. , 1985, European journal of pharmacology.

[32]  A. Lajtha,et al.  Effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age-related changes in dopamine turnover and transporter function in the mouse striatum. , 1985, European journal of pharmacology.

[33]  A. Carlsson,et al.  Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain , 1985, Neuropharmacology.

[34]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[35]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[36]  E. Sundström,et al.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. , 1985, European journal of pharmacology.

[37]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[38]  L. Olson,et al.  Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse , 1985, Journal of neurochemistry.

[39]  D. Felten,et al.  MPTP alters central catecholamine neurons in addition to the nigrostriatal system , 1984, Brain Research Bulletin.

[40]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[41]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[42]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[43]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[44]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[45]  S. Markey,et al.  Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. , 1984, European journal of pharmacology.

[46]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[47]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[49]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[50]  S. Harik,et al.  Strain differences in systematic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier , 1988 .

[51]  R. Duvoisin,et al.  Protection against the Nigrostriatal Dopaminergic Neurotoxicity of 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in Mice by Monoamine Oxidase Inhibitors , 1986 .